Transfusion-Transmitted Cytomegalovirus Infection (TT-CMV): A Pilot Study on Safety of Whole-Blood Derivatives

Mishar  Kelishadi; Abdolvahab  Moradi; Sobhan  Samadi; Pezhman  Hashemi; Masoud  Bazouri; Alijan Tabarraei; Alijan Tabarraei

doi:10.5812/scimetr.25718

Transfusion-Transmitted Cytomegalovirus Infection (TT-CMV): A Pilot Study on Safety of Whole-Blood Derivatives

Mishar Kelishadi ¹ , Abdolvahab Moradi ¹ , Sobhan Samadi ¹ , Pezhman Hashemi ¹ , Masoud Bazouri ¹ and Alijan Tabarraei ^{2
, *}

Authors Information

¹ Student Research Committee, Department of Microbiology, Golestan University of Medical Sciences, Gorgan, IR Iran

² Infectious Diseases Research Center, Department of Microbiology, Golestan University of Medical Sciences, Gorgan, IR Iran

Article information

Scimetr: July 31, 2015, 3 (3); e87405
Published Online: July 28, 2015
Article Type: Brief Report
Received: November 29, 2014
Accepted: July 13, 2015
DOI: 10.5812/scimetr.25718

To Cite: Kelishadi M , Moradi A , Samadi S , Hashemi P , Bazouri M , et al. Transfusion-Transmitted Cytomegalovirus Infection (TT-CMV): A Pilot Study on Safety of Whole-Blood Derivatives, Scimetr. 2015 ; 3(3):e87405. doi: 10.5812/scimetr.25718.

Abstract

Background: Transfusion-transmitted cytomegalovirus infection (TT-CMV) is known to cause significant morbidity and mortality in immunosuppressed patients particularly among allograft recipients and infants born with birth weights less than 1.5 kg.
Objectives: This is the first report in Iran showing the prevalence of CMV-DNA in whole blood/red cell components to evaluate safety for patients.
Patients and Methods: 153 units of whole blood or red cell components [CPDA1 RBC (n = 88), washed RBC (n = 50), whole blood CPDA1 (n = 1), whole blood low volume (n = 1) and leukocytes reduced (n = 13)] were selected for the presence of CMV-DNA from two different hospitals in Gorgan. Detection of CMV-DNA in plasma was performed by nested polymerase chain reaction (Nested PCR) using specific primers selected from highly conserved regions of major capsid protein (MCP) gene of human cytomegalovirus. In addition, CMV-IgM antibody of plasma was analyzed by serological methods. Data was analyzed using SPSS software (version 18).
Results: Totally, 2 of 153 (1.3%) whole blood or red cell components had positive results for CMV infection. Both viremia and anti-IgM CMV positivity were 0.65% (1/153), respectively. CMV-DNA was detected in 2/88 CPDA1 RBC, but not in other products.
Conclusions: Unscreened whole-blood derivatives can act as a vehicle for transmission of CMV infection, thus, screening for cytomegalovirus infection should be performed at least for special groups of patients.

Fulltext

References

1. References included in pdf.

Scimetr

Published by: Kowsar

Transfusion-Transmitted Cytomegalovirus Infection (TT-CMV): A Pilot Study on Safety of Whole-Blood Derivatives

Article information

Abstract

Fulltext

References

Readers' Comments

Scimetr

Published by: Kowsar

Transfusion-Transmitted Cytomegalovirus Infection (TT-CMV): A Pilot Study on Safety of Whole-Blood Derivatives

Article information

Abstract

Fulltext

References

Share on:

Readers' Comments:

Readers' Comments